3 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMOCompleted
Study phase A: Prospective Data CollectionObjectives: * What is the time weighted average spent in hypotension (defined as MAP<65 mmHg) during surgery? * What is normal treatment behaviour of hypotension during surgery? (Treatment choice,…
Approved WMORecruiting
This study seeks to demonstrate the effectiveness and safety of the Non-Valved Conduit on the basis of infection. The rationale for infection resistance with the conduit is that Biointegral Surgical No-React® treated products have a well-documented…